01—Abstract
Summary
Summary of the 10-K filed February 27, 2013. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. reported net sales of $1,129.5 milliona for fiscal 2012, a decrease of 1.1% from $1,142.6 million in 2011, with the decline attributed primarily to unfavorable foreign currency translation of 2.0%.
Operating income was $165.8 millionb (14.7% of net sales) versus $174.3 million in 2011, and net income attributable to common shareowners was $97.3 million, or $2.01 per diluted share, compared with $109.6 million, or $2.14 per diluted share, in 2011. The company operates two segments: Research Models and Services (RMS), which accounted for 61.5% of 2012 net sales with an operating margin of 29.1%, and Preclinical Services (PCS), which accounted for 38.5% of net sales with an operating margin of 8.0%. PCS backlog was $213.9 million at December 29, 2012.
The filing discloses a material weakness in internal control over financial reporting as of December 29, 2012, related to segregation of duties, restricted access, changes to vendor and customer master data, transaction-level controls and financial close controls. Management concluded that disclosure controls were not effective, and PricewaterhouseCoopers LLP issued an adverse opinion on internal control while still opining that the financial statements were fairly presented. Management states remediation efforts began in the first quarter of 2013.
Balance sheet and liquidity: total debt was $666.5 millionc, cash and cash equivalents were $109.7 million, and net cash from operating activities was $208.0 million. The company repurchased 1.7 million shares for $61.4 million in 2012 and has $54.8 million remaining under its $750 million repurchase program.
The $350.0 milliond 2.25% Convertible Senior Notes mature in June 2013, and management intends to settle the principal in cash. The company acquired Accugenix for $16.9 million net of cash acquired and agreed to acquire a 75% interest in Vital River for approximately $26.8 million, which closed in the first quarter of 2013.
02—Key points
Key Highlights
- Net sales of $1,129.5 million in 2012, down 1.1% from $1,142.6 million, mainly due to unfavorable foreign currency translation of 2.0%.
- Operating income of $165.8 million (14.7% of net sales) compared with $174.3 million in 2011; diluted EPS of $2.01 versus $2.14.
- RMS segment was 61.5% of net sales with a 29.1% operating margin; PCS segment was 38.5% of net sales with an 8.0% operating margin.
- Material weakness in internal control over financial reporting as of December 29, 2012; PricewaterhouseCoopers LLP's opinion states the company did not maintain effective internal control.
- Total debt of $666.5 million, including $350.0 million of 2.25% Convertible Senior Notes due June 2013 that management intends to settle in cash.
- Operating cash flow of $208.0 million; repurchased 1.7 million shares for $61.4 million in 2012 with $54.8 million remaining under the $750 million program.
- PCS backlog of $213.9 million at December 29, 2012, compared with $202.5 million at December 31, 2011.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2012, Charles River Laboratories International kept $0.09.
- Revenue$1.13B100.0%
- Cost of revenue−$257.7M22.8%
- Gross profit$871.8M77.2%
- Operating costs−$706.1M62.5%
- Operating income$165.8M14.7%
- Interest, other & tax−$68.5M6.1%
- Net income$97.3M8.6%
Where FY2012 revenue went
$1.13B- Other operating costs: $497.8M, 44% of revenue
- Cost of revenue: $257.7M, 23% of revenue
- SG&A: $208.2M, 18% of revenue
- Net income: $97.3M, 8.6% of revenue
- Interest, other & tax: $68.5M, 6.1% of revenue
Kept 8.6% as net incomeNet income $97.3M · 8.6%
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2012filed February 27, 2013Financial Statements
FY2012 against FY2011
| Line item | FY2012FY2011 | Change |
|---|---|---|
| Revenue | $1.13B$1.14B | −1.1% |
| Cost of Revenue | $257.71M$267.97M | −3.8% |
| Gross Profit | $871.82M$874.68M | −0.3% |
| SG&A Expenses | $208.25M$198.65M | +4.8% |
| Operating Income | $165.76M$174.31M | −4.9% |
| Interest Expense | $33.34M$42.59M | −21.7% |
| Net Income | $97.30M$109.98M | −11.5% |
| EPS (Basic) | $2.03$2.16 | −6.0% |
| EPS (Diluted) | $2.01$2.14 | −6.1% |
| Shares Outstanding (Basic) | 47.91M50.82M | −5.7% |
| Shares Outstanding (Diluted) | 48.41M51.32M | −5.7% |
05—Questions
Frequently Asked Questions
Why did net sales decline in 2012?
The filing attributes the 1.1% decrease in net sales, to $1,129.5 million, primarily to unfavorable foreign currency translation, which reduced sales by 2.0%. The 53rd week recognized in 2011 reduced 2012 sales growth by 1.1%. The RMS segment declined 1.5% on lower research model sales, partly offset by growth in EMD and research model services, while PCS declined 0.6% on unfavorable currency and reduced biopharmaceutical spending.
What is the material weakness and how is the company responding?
Management identified deficiencies in controls over segregation of duties, restricted access, changes to vendor and customer master data, transaction-level controls and financial close controls, which together constitute a material weakness as of December 29, 2012. Management reports that in the first quarter of 2013 it established a cross-functional team to address segregation of duties and restricted access in IT systems, and it plans to design new or improved controls, evaluate staffing levels and increase training. Management also states it performed additional procedures and believes the 2012 financial statements are fairly stated in all material respects.
How is the company's debt structure and near-term maturity exposure?
Total debt was $666.5 million at December 29, 2012. Of this, the 2.25% Convertible Senior Notes of $350.0 million are due June 2013, and the company intends to settle principal in cash using existing credit facility capacity, existing cash and marketable securities, or other financing. The credit agreement provides a $299.8 million term loan, a €69.4 million Euro term loan and a $350 million revolving facility maturing September 23, 2016. Current portion of long-term debt and capital leases was $139.4 million.
What did the company say about its strategy and recent acquisitions?
The company's four key initiatives are improving consolidated operating margin, improving free cash flow, disciplined investment in growth businesses, and returning value to shareholders. In 2012 it acquired Accugenix for $16.9 million net of cash acquired to expand its EMD business. It agreed in October 2012 to acquire a 75% interest in Vital River, a China research models provider, for approximately $26.8 million, which closed in the first quarter of 2013. Management expects 2013 capital expenditures of approximately $50.0 million.
What are the main risks to the business highlighted in the filing?
The filing highlights risks including a possible decline in preclinical outsourcing, reductions in pharmaceutical and biotechnology R&D budgets and government (NIH) funding, the fact that client contracts are generally terminable on little or no notice, many fixed-price contracts that can lead to losses, goodwill impairment risk with $293.5 million of goodwill and other intangibles, and international operations, which represented approximately one-half of total net sales in recent years. The company also reported a material weakness in internal controls.
06—Continue